5.98
price up icon4.91%   0.28
pre-market  Pre-mercato:  5.98  
loading
Precedente Chiudi:
$5.70
Aprire:
$5.69
Volume 24 ore:
2.84M
Relative Volume:
1.64
Capitalizzazione di mercato:
$792.62M
Reddito:
-
Utile/perdita netta:
$-29.07M
Rapporto P/E:
-20.62
EPS:
-0.29
Flusso di cassa netto:
$-31.85M
1 W Prestazione:
+5.28%
1M Prestazione:
-5.30%
6M Prestazione:
+37.16%
1 anno Prestazione:
+123.13%
Intervallo 1D:
Value
$5.53
$6.075
Intervallo di 1 settimana:
Value
$5.41
$6.075
Portata 52W:
Value
$2.36
$7.48

Trevi Therapeutics Inc Stock (TRVI) Company Profile

Name
Nome
Trevi Therapeutics Inc
Name
Telefono
203-304-2499
Name
Indirizzo
195 CHURCH STREET, NEW HAVEN, CT
Name
Dipendente
31
Name
Cinguettio
@TreviThera
Name
Prossima data di guadagno
2025-03-18
Name
Ultimi documenti SEC
Name
TRVI's Discussions on Twitter

Confronta TRVI con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
TRVI
Trevi Therapeutics Inc
5.98 792.62M 0 -29.07M -31.85M -0.29
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-28 Iniziato H.C. Wainwright Buy
2025-03-10 Reiterato Needham Buy
2025-03-10 Aggiornamento Raymond James Outperform → Strong Buy
2024-12-12 Reiterato H.C. Wainwright Buy
2024-09-09 Ripresa Leerink Partners Outperform
2024-08-30 Iniziato H.C. Wainwright Buy
2024-08-30 Iniziato Raymond James Outperform
2024-06-13 Iniziato Rodman & Renshaw Buy
2023-04-12 Iniziato B. Riley Securities Buy
2022-11-22 Iniziato SVB Leerink Outperform
2019-06-03 Iniziato BMO Capital Markets Outperform
2019-06-03 Iniziato Needham Buy
2019-06-03 Iniziato SVB Leerink Outperform
2019-06-03 Iniziato Stifel Buy
Mostra tutto

Trevi Therapeutics Inc Borsa (TRVI) Ultime notizie

pulisher
Jun 17, 2025

Trevi Therapeutics Stockholders Approve Key Amendments - TipRanks

Jun 17, 2025
pulisher
Jun 14, 2025

Leerink Partnrs Issues Optimistic Estimate for TRVI Earnings - Defense World

Jun 14, 2025
pulisher
Jun 12, 2025

Oppenheimer Raises Price Target for Trevi Therapeutics by $3 - MSN

Jun 12, 2025
pulisher
Jun 11, 2025

Squarepoint Ops LLC Acquires Shares of 14,059 Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Jun 11, 2025
pulisher
Jun 09, 2025

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares - Eastern Progress

Jun 09, 2025
pulisher
Jun 09, 2025

WilmerHale Advises Trevi Therapeutics, Inc. in $115 Million Public Offering - WilmerHale

Jun 09, 2025
pulisher
Jun 09, 2025

Two Sigma Advisers LP Invests $66,000 in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Jun 09, 2025
pulisher
Jun 09, 2025

Two Sigma Investments LP Purchases New Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Trevi Therapeutics (NASDAQ:TRVI) Rating Lowered to “Sell” at Wall Street Zen - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Purchased by Millennium Management LLC - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins - insights.citeline.com

Jun 05, 2025
pulisher
Jun 05, 2025

Trevi Therapeutics Closes Public Offering - MarketScreener

Jun 05, 2025
pulisher
Jun 05, 2025

Trevi Therapeutics Announces Closing of $115 Million Underwritte - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares | TRVI Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Trevi Therapeutics Secures Massive $115M Funding: Investors Rush to Back Chronic Cough Treatment Developer - Stock Titan

Jun 05, 2025
pulisher
Jun 05, 2025

Trevi Therapeutics Announces Pricing of $100 Million Underwritte - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Sold by BNP Paribas Financial Markets - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

Ameriprise Financial Inc. Acquires 63,067 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Trevi Therapeutics Prices $100 Mln Public Offering Of Common Stock - Nasdaq

Jun 04, 2025
pulisher
Jun 04, 2025

Trevi Therapeutics Announces Public Offering Pricing - TipRanks

Jun 04, 2025
pulisher
Jun 04, 2025

Trevi Therapeutics IncExpects Cash Resources To Fund Operations Into 2029 - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock - Eastern Progress

Jun 04, 2025
pulisher
Jun 04, 2025

Trevi Therapeutics Announces Proposed Public Offering of Common Stock - Longview News-Journal

Jun 04, 2025
pulisher
Jun 04, 2025

Trevi Therapeutics Prices $100 Million Common Stock Offering - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

ProShare Advisors LLC Buys 9,589 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

Biotech Trevi Therapeutics Secures Major $100M Financing Through Stock Offering - Stock Titan

Jun 04, 2025
pulisher
Jun 03, 2025

Trevi Therapeutics Announces Pricing Of $100 Million Underwritten Offering Of Common Stock - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

H.C. Wainwright maintains Trevi Therapeutics stock rating following trial results - Investing.com Canada

Jun 03, 2025
pulisher
Jun 03, 2025

Oppenheimer Boosts Trevi Therapeutics (TRVI) PT to $23, Cites Positive Haduvio Trial Results - Insider Monkey

Jun 03, 2025
pulisher
Jun 03, 2025

Stifel reiterates buy rating for Trevi Therapeutics stock after study results - Investing.com Canada

Jun 03, 2025
pulisher
Jun 03, 2025

Oppenheimer Adjusts Price Target on Trevi Therapeutics to $23 From $20, Maintains Outperform Rating - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Trevi Therapeutics stock soars to 52-week high of $7.43 By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

Trevi Therapeutics launches $100 million stock offering By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

Trevi Therapeutics (NASDAQ:TRVI) Given “Buy” Rating at D. Boral Capital - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Trevi Therapeutics stock soars to 52-week high of $7.43 - Investing.com India

Jun 03, 2025
pulisher
Jun 02, 2025

Trevi Therapeutics Terminates ATM Prospectus with Leerink - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

Oppenheimer raises Trevi Therapeutics stock price target to $23 By Investing.com - Investing.com UK

Jun 02, 2025
pulisher
Jun 02, 2025

Trevi Therapeutics launches $100 million stock offering - Investing.com Australia

Jun 02, 2025
pulisher
Jun 02, 2025

Trevi Therapeutics Plans $100 Million Stock Sale; Shares Sliding in After-Hours Trade - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Oppenheimer Boosts Trevi Therapeutics (TRVI) Price Target to $23 | TRVI Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Trevi Therapeutics (TRVI) Receives "Buy" Rating from D. Boral Capital | TRVI Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Trevi Therapeutics Announces Proposed Public Offering Of Common Stock - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Trevi Therapeutics (TRVI) Launches $100M Public Offering | TRVI Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Trevi Therapeutics Announces Proposed Public Offering of Common Stock | TRVI Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients - Benzinga

Jun 02, 2025
pulisher
Jun 02, 2025

trevi therapeutics reports positive results from phase 2b cough trial By Investing.com - Investing.com Australia

Jun 02, 2025

Trevi Therapeutics Inc Azioni (TRVI) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Trevi Therapeutics Inc Azioni (TRVI) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
SCIASCIA THOMAS
Chief Scientific Officer
Mar 25 '25
Sale
6.60
2,631
17,365
221,373
GOOD JENNIFER L
President & CEO
Mar 21 '25
Option Exercise
1.43
5,263
7,526
218,576
GOOD JENNIFER L
President & CEO
Mar 21 '25
Sale
6.58
5,263
34,625
213,313
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):